CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 68 enrolled
Drug / intervention
Active bevacizumab and Sham dexamethasone +1 moredrug
Likely dose
Active bevacizumab and Sham dexamethasone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01295112
NCT01295112Phase 3Completed
CompareCT.gov

Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion

Texas Retina Associates·interventional·Posted Feb 14, 2011·Updated Sep 25, 2025

In Brief

A Phase 3 clinical trial evaluating Active bevacizumab and Sham dexamethasone and Active bevacizumab and Active dexamethasone for Non-Ischemic Central Retinal Vein Occlusion. Completed, enrolled 68 participants across 1 site.

Detailed Summary

This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Ischemic Central Retinal Vein Occlusion
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 14, 2011
Enrollment StartMay 1, 2011
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.4 years ago

Interventions

Active bevacizumab and Sham dexamethasonedrug

Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe

Active bevacizumab and Active dexamethasonedrug

Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose